Brind.
  1. Trump-era tariffs may benefit AI stocks, while Google faces DOJ rulings and secures a default search engine deal with Apple.
  2. AI stocks are benefiting from the trend of onshoring and tariffs implemented during the Trump era.
  3. Trump-era tariffs are benefiting AI stocks, and the FDA expanded the patient base for WAKIX.
  4. Tariffs benefit AI stocks, and Radiopharm Theranostics Limited received IND approval from the FDA.

Inflarx conducts research in Germany, Trump-era tariffs benefit certain AI stocks, and the FDA granted EUA for GOHIBIC treatment.

1 report, 1 independent Updated Jul 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Inflarx conducts research in Germany, Trump-era tariffs benefit certain AI stocks, and the FDA granted EUA for GOHIBIC treatment.

Who's involved

What this event is mainly about
FDADonald TrumpInflarx (Germany)

Keep exploring

Part of

Tariffs benefit AI stocks, and Radiopharm Theranostics Limited received IND approval from the FDA. All 3 developments

Within Trump-era tariffs may benefit AI stocks, while Google faces DOJ rulings and secures a default search engine deal with Apple.

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Insider MonkeyInflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now. As May came to an end